Assenagon Asset Management
CGEM icon

Assenagon Asset Management’s Cullinan Oncology CGEM Stock Holding History

Assenagon Asset Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Sell
61,682
-77,023
-56% -$1.14M ﹤0.01% 956
2026
Q1 		$1.97M Sell
138,705
-20,048
-13% -$258K ﹤0.01% 779
2025
Q4 		$1.64M Sell
158,753
-18,932
-11% -$171K ﹤0.01% 856
2025
Q3 		$1.05M Buy
177,685
+167,623
+1,666% +$1.23M ﹤0.01% 926
2025
Q2 		$75.8K Hold
10,062
– – ﹤0.01% 1140
2025
Q1 		$76.2K Sell
10,062
-123,198
-92% -$1.18M ﹤0.01% 1134
2024
Q4 		$1.62M Sell
133,260
-1,776
-1% -$25.5K ﹤0.01% 1002
2024
Q3 		$2.26M Buy
135,036
+20,841
+18% +$370K ﹤0.01% 928
2024
Q2 		$1.99M Buy
+114,195
New +$2.43M ﹤0.01% 905
2023
Q4 		– Sell
-609,106
Closed -$5.51M – 1412
2023
Q3 		$5.51M Buy
609,106
+482,234
+380% +$5.02M 0.02% 555
2023
Q2 		$1.37M Sell
126,872
-94,468
-43% -$1M ﹤0.01% 890
2023
Q1 		$2.26M Buy
221,340
+138,330
+167% +$1.52M 0.01% 793
2022
Q4 		$876K Buy
+83,010
New +$1.01M ﹤0.01% 1072

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Assenagon Asset Management's CGEM Position: Q2 2026 in Review

Assenagon Asset Management reduced its Cullinan Oncology (CGEM) stake by 56% in Q2 2026, selling an estimated $1.14M and leaving 61,682 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #956.

Assenagon Asset Management first reported a position in CGEM in Q4 2022 and has held it in 13 quarters since. The position peaked at $5.51M in Q3 2023. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Assenagon Asset Management held 61,682 shares of Cullinan Oncology worth $1.12M as of Q2 2026.
  • Assenagon Asset Management sold 77,023 Cullinan Oncology shares in Q2 2026, an estimated $1.14M.
  • Cullinan Oncology made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #956 holding.
  • Assenagon Asset Management first reported a position in Cullinan Oncology in Q4 2022 and has held it in 13 quarters since.
  • Assenagon Asset Management's Cullinan Oncology position peaked at $5.51M in Q3 2023.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.